Prognostic implications of creatine kinase-mb elevation after percutaneous coronary intervention: Results from the evaluation of drug-eluting stents and ischemic events (EVENT) registry

Circulation: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 474-480

  Lindsey, Jason B ^a   Kennedy, Kevin F ^a   Stolker, Joshua M ^a   Gilchrist, Ian C ^b   Mukherjee, Debabrata ^c   Marso, Steven P ^a   Pencina, Michael J ^d   Kleiman, Neal S ^e   Cohen, David J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Creatine kinase; Mortality prognosis; Myonecrosis; Percutaneous coronary intervention

Indexed keywords

CREATINE KINASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; DISEASE REGISTRY; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY; COHORT STUDIES; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; REFERENCE VALUES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 82955229548     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.962233     Document Type: Article

References (26)

1. Wang TY, Peterson ED, Dai D, Anderson HV, Rao SV, Brindis RG, Roe MT. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008;51: 2068-2074. (Pubitemid 351680519)
2. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411. (Pubitemid 37267281)
3. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation. 2002;105:554-556. (Pubitemid 34123427)
4. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104: 642-647. (Pubitemid 32738516)
5. Kini A, Kini S, Marmur JD, Bertea T, Dangas G, Cocke TP, Sharma SK. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv. 1999;48:123-129. (Pubitemid 29458306)
6. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 2002;40:1961-1967. (Pubitemid 35428831)
7. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol. 1995;25: 1693-1699.
8. Kugelmass AD, Cohen DJ, Moscucci M, Piana RN, Senerchia C, Kuntz RE, Baim DS. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748-754. (Pubitemid 24312963)
9. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation. 1998;97:322-331. (Pubitemid 28074332)
10. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466. (Pubitemid 27074329)
11. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med. 2011;364:453-464.
12. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention: EPIC Investigator Group: evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA. 1997;278:479-484. (Pubitemid 27344001)
13. Andron M, Stables RH, Egred M, Alahmar AE, Shaw MA, Roberts E, Albouaini K, Grayson AD, Perry RA, Palmer ND. Impact of periprocedural creatine kinase-MB isoenzyme release on long-term mortality in contemporary percutaneous coronary intervention. J Invasive Cardiol. 2008;20:108-112. (Pubitemid 351346270)
14. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23: 869-876. (Pubitemid 34717422)
15. Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-STsegment elevation acute coronary syndrome (from the international trial SYNERGY). Am J Cardiol. 2009;104:1330-1335.
16. Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, Kleiman N. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J. 2005;150:887-892. (Pubitemid 41607758)
17. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29:1037-1057.
18. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC investigation. N Engl J Med. 1994;330:956-961.
19. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863. (Pubitemid 37430344)
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
21. CathPCI registry V4 outcomes companion guide. Washington, DC: American College of Cardiology Foundation; 2010.
22. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008;52:807-814.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
24. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361: 2330-2341.
25. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121:43-51.
26. Jeremias A, Baim DS, Ho KK, Chauhan M, Carrozza JP Jr, Cohen DJ, Popma JJ, Kuntz RE, Cutlip DE. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol. 2004;44:1210-1214. (Pubitemid 39208875)